Pub Date : 2020-12-06DOI: 10.21608/ebwhj.2019.17469.1024
Ebtsam Desouky, Alaa El Feky, Amr A. Elsayed
Background: Termination of pregnancy (TOP) is defined as elective expulsion or extraction of products of conception from the uterus instead of spontaneous onset of the process irrespective of duration of pregnancy. Aim of the Work: to investigate whether the insertion of a weighted fluid filled trans-cervical Foley’s catheter in women undergoing midtrimester termination of pregnancy for various reasons; may further improve the effectiveness of vaginal misoprostol in terminating their pregnancies. Patients and Methods: A prospective, interventional, randomized controlled trial was conducted on a total number of 50 patients, divided into two groups; the first group (I) included 25 patients who received vaginal misoprostol, two tablets each contains 200 microgram misoprostol (Segma pharmaceuticals, Egypt), in the posterior vaginal fornix every four hours. Results: The use of a weighted trans-cervical Foley’s catheter filled with 30 ml saline improve the effectiveness of 400 µg vaginal misoprostol in terminating mid trimester pregnancies as reflected by a shorter induction to delivery interval with no significant increase in the incidence of side effects. Conclusion: The use of a weighted trans-cervical Foley’s catheter filled with 30 ml saline improve the effectiveness of 400 µg vaginal misoprostol in terminating mid trimester pregnancies as reflected by a shorter induction to delivery interval with no significant increase in the incidence of side effects.
{"title":"Randomized controlled trial between vaginal misoprostol alone versus weighted intrauterine Foley’s catheter and vaginal misoprostol in termination of mid-trimester abortion","authors":"Ebtsam Desouky, Alaa El Feky, Amr A. Elsayed","doi":"10.21608/ebwhj.2019.17469.1024","DOIUrl":"https://doi.org/10.21608/ebwhj.2019.17469.1024","url":null,"abstract":"Background: Termination of pregnancy (TOP) is defined as elective expulsion or extraction of products of conception from the uterus instead of spontaneous onset of the process irrespective of duration of pregnancy. Aim of the Work: to investigate whether the insertion of a weighted fluid filled trans-cervical Foley’s catheter in women undergoing midtrimester termination of pregnancy for various reasons; may further improve the effectiveness of vaginal misoprostol in terminating their pregnancies. Patients and Methods: A prospective, interventional, randomized controlled trial was conducted on a total number of 50 patients, divided into two groups; the first group (I) included 25 patients who received vaginal misoprostol, two tablets each contains 200 microgram misoprostol (Segma pharmaceuticals, Egypt), in the posterior vaginal fornix every four hours. Results: The use of a weighted trans-cervical Foley’s catheter filled with 30 ml saline improve the effectiveness of 400 µg vaginal misoprostol in terminating mid trimester pregnancies as reflected by a shorter induction to delivery interval with no significant increase in the incidence of side effects. Conclusion: The use of a weighted trans-cervical Foley’s catheter filled with 30 ml saline improve the effectiveness of 400 µg vaginal misoprostol in terminating mid trimester pregnancies as reflected by a shorter induction to delivery interval with no significant increase in the incidence of side effects.","PeriodicalId":224226,"journal":{"name":"Evidence Based Womenʼs Health Journal","volume":"27 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2020-12-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"128735505","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-12-06DOI: 10.21608/ebwhj.2020.26277.1084
D. Khalifa, A. Mohamed, M. Elsersi
Background: Pre-eclampsia is a disorder of widespread vascular endothelial malfunction and vasospasm that occurs after 20 weeks' gestation.Aim of the Work: comparing the anti-hypertensive efficacy of oral Labetalol with oral Nifedipine in mild preeclampsia .Patients and Methods: This study was conducted on a total of 100 antenatal mild full term preeclamptic women at Ain Shams University maternity hospital ICU and obstetric theater. They were divided into two groups: First group (group A): Oral Labetalol was started with a dose of 200 mg and Second group (group B): Oral Nifedipine was started at dose of 20 mg. Results: group B had significantly higher number of side effects when compared to group A. None of the patients developed grave complications such as HELLP syndrome, pulmonary edema, coagulopathy, postpartum collapse, the maternal mortality was nil. Thus when patients with preeclampsia are identified and treated at an earlier stage the morbidity and mortality associated with preeclampsia can be significantly reduced.Conclusion: Both Oral Labetalol and oral Nifedipine are equally efficacious in the control of hypertension in mild preeclampsia. Regarding the drug side effects and tolerability, Labetalol was significantly better than. Nifedipine. There was no significant difference in the neonatal outcome between the two groups. Thus Labetalol is a better alternative to Nifedipine, as it had lesser side effect profile. But in a limited resource setting, Nifedipine is an equally effective, cheap and easily available drug for mild preeclampsia.
{"title":"Pre-operative Preparation of Pre-eclamptic Patients Undergoing Cesarean Section: A prospective randomized comparative study between the effect of Labetalol versus Nifedipine in controlling elevation of blood pressure","authors":"D. Khalifa, A. Mohamed, M. Elsersi","doi":"10.21608/ebwhj.2020.26277.1084","DOIUrl":"https://doi.org/10.21608/ebwhj.2020.26277.1084","url":null,"abstract":"Background: Pre-eclampsia is a disorder of widespread vascular endothelial malfunction and vasospasm that occurs after 20 weeks' gestation.Aim of the Work: comparing the anti-hypertensive efficacy of oral Labetalol with oral Nifedipine in mild preeclampsia .Patients and Methods: This study was conducted on a total of 100 antenatal mild full term preeclamptic women at Ain Shams University maternity hospital ICU and obstetric theater. They were divided into two groups: First group (group A): Oral Labetalol was started with a dose of 200 mg and Second group (group B): Oral Nifedipine was started at dose of 20 mg. Results: group B had significantly higher number of side effects when compared to group A. None of the patients developed grave complications such as HELLP syndrome, pulmonary edema, coagulopathy, postpartum collapse, the maternal mortality was nil. Thus when patients with preeclampsia are identified and treated at an earlier stage the morbidity and mortality associated with preeclampsia can be significantly reduced.Conclusion: Both Oral Labetalol and oral Nifedipine are equally efficacious in the control of hypertension in mild preeclampsia. Regarding the drug side effects and tolerability, Labetalol was significantly better than. Nifedipine. There was no significant difference in the neonatal outcome between the two groups. Thus Labetalol is a better alternative to Nifedipine, as it had lesser side effect profile. But in a limited resource setting, Nifedipine is an equally effective, cheap and easily available drug for mild preeclampsia.","PeriodicalId":224226,"journal":{"name":"Evidence Based Womenʼs Health Journal","volume":"74 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2020-12-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"128381702","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-12-06DOI: 10.21608/ebwhj.2020.28038.1088
Heba M Haggag, H. Allam, Ayman Abo El-nour, H. El-Shahawy
Background: Medical abortion, the termination of pregnancy through the use of a drug or a combination of drugs, has the potential to reduce complications and to expand access to abortion provided not only by specially trained clinicians but also by other health care providers who may or may not have training in surgical methods of abortion. Aim of the work: to elicit the safety and efficacy of intravenous injection of dexamethasone with vaginal misoprostol for shortening the induction – abortion interval in the second trimester of pregnancy. Patients and Methods: This study was conducted in Ain Shams Maternity University Hospital where 140 pregnant females were included for induction of second trimester abortion from June 2018 till December 2019. Results: There was significant statistical difference between the two groups as regard induction-expulsion interval (P >0.001) and length of hospital stay (P > 0.001), mean induction-expulsion interval in dexamethasone group was (10.5 hours) while in control group was (17.5 hours) , the mean length hospital stay was 16 hours in the dexamethasone group while was 23 hours in the control group. There was significant statistical difference between the two groups as regard dose of misoprostol used (P>0.001),mean dose of misoprostol in the dexamethasone group was 800 mcg while was 1600 mcg in the control group. Conclusion: suggested that use of intravenous injection of dexamethasone with misoprostol was effective in shortening the induction- abortion interval, the length of hospital stay and reducing the misoprostol doses.
{"title":"Effect of Intravenous Dexamethasone on Induction of Mid-Trimesteric Abortion Randomized Controlled Trial","authors":"Heba M Haggag, H. Allam, Ayman Abo El-nour, H. El-Shahawy","doi":"10.21608/ebwhj.2020.28038.1088","DOIUrl":"https://doi.org/10.21608/ebwhj.2020.28038.1088","url":null,"abstract":"Background: Medical abortion, the termination of pregnancy through the use of a drug or a combination of drugs, has the potential to reduce complications and to expand access to abortion provided not only by specially trained clinicians but also by other health care providers who may or may not have training in surgical methods of abortion. Aim of the work: to elicit the safety and efficacy of intravenous injection of dexamethasone with vaginal misoprostol for shortening the induction – abortion interval in the second trimester of pregnancy. Patients and Methods: This study was conducted in Ain Shams Maternity University Hospital where 140 pregnant females were included for induction of second trimester abortion from June 2018 till December 2019. Results: There was significant statistical difference between the two groups as regard induction-expulsion interval (P >0.001) and length of hospital stay (P > 0.001), mean induction-expulsion interval in dexamethasone group was (10.5 hours) while in control group was (17.5 hours) , the mean length hospital stay was 16 hours in the dexamethasone group while was 23 hours in the control group. There was significant statistical difference between the two groups as regard dose of misoprostol used (P>0.001),mean dose of misoprostol in the dexamethasone group was 800 mcg while was 1600 mcg in the control group. Conclusion: suggested that use of intravenous injection of dexamethasone with misoprostol was effective in shortening the induction- abortion interval, the length of hospital stay and reducing the misoprostol doses.","PeriodicalId":224226,"journal":{"name":"Evidence Based Womenʼs Health Journal","volume":"146 3 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2020-12-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"129797770","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-12-06DOI: 10.21608/ebwhj.2020.26232.1082
N. Sakna, M. A. N. A. Gawad, Enas Elshahid, Ahmed Atik
Background: Intrauterine contraceptive devices (IUCDs) are one of the reversible effective contraceptives. However its use is limited by the high cost in some settings and fear of pain at insertion time. Objectives: The aim of the study was to evaluate the role of vaginal misoprostol (400microgram) administration 3h prior to intrauterine contraceptive device (IUCD) insertion in women delivered only by elective caesarean section.Patients and Methods: A double-blind randomised controlled trial was conducted in 210 women who were eligible for IUD insertion. Participants were randomly divided to receive either 400 microgram vaginal misoprostol or placebo 3h before IUD insertion. The primary outcome measure was insertion difficulty score. Secondary outcome measures were the pain score during the procedur, complications of IUD insertion and side effects related to misoprostol. Results: Insertion difficulty and pain scores were significantly lower in the misoprostol group compared with the placebo group ( 89 [84.8%] vs. 41 [39.0%]; p < 0.001 and 1.3±0.6 vs. 2.5±1.2; p < 0.001 respectively). More women experienced nausea, vomiting (10 vs. 0; p < 0.001) and shievering (6 vs. 0; p < 0.029) in the misoprostol group than in the placebo group, respectively. Conclusion: The study concluded that using of misoprostol at a dose of 400 microgram administered vaginally 3 hours prior to IUCD insertion in women who delivered only by elective cesarean section had significant effect on increase easiness of insertion and reduce the incidence of pain during the procedure.
背景:宫内节育器(IUCDs)是一种可逆的有效避孕方法。然而，在某些情况下，它的使用受到高成本和插入时对疼痛的恐惧的限制。目的:本研究的目的是评估米索前列醇(400微克)阴道给药前3h的宫内节育器(IUCD)插入妇女只分娩择期剖宫产。患者和方法:对210例符合宫内节育器置入条件的妇女进行双盲随机对照试验。参与者在宫内节育器插入前3小时随机分为400微克阴道米索前列醇组和安慰剂组。主要结局指标为插入难度评分。次要观察指标为术中疼痛评分、宫内节育器植入并发症及米索前列醇相关副作用。结果:米索前列醇组插入困难和疼痛评分明显低于安慰剂组(89分[84.8%]比41分[39.0%];P < 0.001和1.3±0.6 vs. 2.5±1.2;P < 0.001)。更多的女性出现恶心、呕吐(10比0;P < 0.001)和颤抖(6 vs. 0;P < 0.029)，米索前列醇组与安慰剂组比较差异有统计学意义。结论:仅择期剖宫产分娩的妇女在宫内节育器置入前3小时阴道给予米索前列醇400微克，对增加宫内节育器置入的容易程度和减少术中疼痛发生率有显著效果。
{"title":"Vaginal Misoprostol Prior to Intrauterine Contraceptive Device Insertion in Women Who Delivered Only By Elective Caeserean Section: Randomized Clinical Trial","authors":"N. Sakna, M. A. N. A. Gawad, Enas Elshahid, Ahmed Atik","doi":"10.21608/ebwhj.2020.26232.1082","DOIUrl":"https://doi.org/10.21608/ebwhj.2020.26232.1082","url":null,"abstract":"Background: Intrauterine contraceptive devices (IUCDs) are one of the reversible effective contraceptives. However its use is limited by the high cost in some settings and fear of pain at insertion time. Objectives: The aim of the study was to evaluate the role of vaginal misoprostol (400microgram) administration 3h prior to intrauterine contraceptive device (IUCD) insertion in women delivered only by elective caesarean section.Patients and Methods: A double-blind randomised controlled trial was conducted in 210 women who were eligible for IUD insertion. Participants were randomly divided to receive either 400 microgram vaginal misoprostol or placebo 3h before IUD insertion. The primary outcome measure was insertion difficulty score. Secondary outcome measures were the pain score during the procedur, complications of IUD insertion and side effects related to misoprostol. Results: Insertion difficulty and pain scores were significantly lower in the misoprostol group compared with the placebo group ( 89 [84.8%] vs. 41 [39.0%]; p < 0.001 and 1.3±0.6 vs. 2.5±1.2; p < 0.001 respectively). More women experienced nausea, vomiting (10 vs. 0; p < 0.001) and shievering (6 vs. 0; p < 0.029) in the misoprostol group than in the placebo group, respectively. Conclusion: The study concluded that using of misoprostol at a dose of 400 microgram administered vaginally 3 hours prior to IUCD insertion in women who delivered only by elective cesarean section had significant effect on increase easiness of insertion and reduce the incidence of pain during the procedure.","PeriodicalId":224226,"journal":{"name":"Evidence Based Womenʼs Health Journal","volume":"9 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2020-12-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"125765233","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-12-06DOI: 10.21608/ebwhj.2019.17526.1031
Magdy Abdelgawad, D. Mansour, Mohammed A Mohammed
Background: High doses of iron lead to gastrointestinal intolerance. Aim of this Work: to compare the hemoglobin levels in non anemic pregnant women receiving weekly versus daily iron supplementation. Patients and Methods: This randomized controlled clinical trial was conducted 140 patients from October 2017 to December 2018 at Ain-Shams University Maternity hospital. Divided into two groups: Group A: (weekly group) received 2 capsules of 100 mg elemental iron (from 305mg ferrous fumarate) plus 2 mg of folic acid (Ferro — 6 - Pharco - Egypt) once weekly. Group B: (daily group) received one capsule of 100 mg elemental iron (from 305mg ferrous fumarate) plus 2 mg of folic acid (Ferro - 6 - Pharco - Egypt) once daily. Results: There were no statistically significant difference between both groups as regards the hemoglobin level after one month of iron supplementation and after three months of iron supplementation. Although the mean hemoglobin concentration at 36 weeks gestation was lower in the weekly supplementation group it did not reach the level of statistical significance. There was significant increase in the incidence of iron side-effects mainly gastrointestinal side-effects in group B (Daily group). There was no statistically significant difference could be detected between both groups as regards the fetal weight. Conclusion: weekly iron supplementation as a prophylaxis in non-anemic pregnant women is as good as daily supplementation as regards the hemoglobin level in addition; it was associated with significantly fewer side-effects and much better compliance.
{"title":"Daily Versus Weekly Oral Iron Supplementation in Pregnant Women (A Randomized Controlled Clinical Trial)","authors":"Magdy Abdelgawad, D. Mansour, Mohammed A Mohammed","doi":"10.21608/ebwhj.2019.17526.1031","DOIUrl":"https://doi.org/10.21608/ebwhj.2019.17526.1031","url":null,"abstract":"Background: High doses of iron lead to gastrointestinal intolerance. Aim of this Work: to compare the hemoglobin levels in non anemic pregnant women receiving weekly versus daily iron supplementation. Patients and Methods: This randomized controlled clinical trial was conducted 140 patients from October 2017 to December 2018 at Ain-Shams University Maternity hospital. Divided into two groups: Group A: (weekly group) received 2 capsules of 100 mg elemental iron (from 305mg ferrous fumarate) plus 2 mg of folic acid (Ferro — 6 - Pharco - Egypt) once weekly. Group B: (daily group) received one capsule of 100 mg elemental iron (from 305mg ferrous fumarate) plus 2 mg of folic acid (Ferro - 6 - Pharco - Egypt) once daily. Results: There were no statistically significant difference between both groups as regards the hemoglobin level after one month of iron supplementation and after three months of iron supplementation. Although the mean hemoglobin concentration at 36 weeks gestation was lower in the weekly supplementation group it did not reach the level of statistical significance. There was significant increase in the incidence of iron side-effects mainly gastrointestinal side-effects in group B (Daily group). There was no statistically significant difference could be detected between both groups as regards the fetal weight. Conclusion: weekly iron supplementation as a prophylaxis in non-anemic pregnant women is as good as daily supplementation as regards the hemoglobin level in addition; it was associated with significantly fewer side-effects and much better compliance.","PeriodicalId":224226,"journal":{"name":"Evidence Based Womenʼs Health Journal","volume":"21 5","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2020-12-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"132433216","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-12-06DOI: 10.21608/ebwhj.2019.17524.1030
M. Elmahallawi, M.R.C.O.G. Abdel-Hafeez, A. Hussein, Reham Mahmoud
Background: Global prevalence of anemia in pregnant women is 41.8%, approximately 50% of cases of anemia are considered to be due to iron deficiency. Aim of the Work: to assess the prevalence of anemia and its complications among term pregnant women at Ain Shams University Maternity Hospital. Patients and Methods: This retrospective study was conducted on hospital records of 1552 pregnant women from January 2018 to July 2018 . Results: Hb was 11.3±1.4 gm/dL, 59.1% of patients were normal and 40.9% had anemia in form of Mild in 28.3%, Moderate in 11.3% and Severe in 1.3%.. As regard neonatal outcome mean gestational age was 38.8±0.9 weeks, birth weight 3.13±0.56 kg, Apgar 1st was 8.4±1.2, 5th was 8.5±1.1. As regard neonatal complications 9.35 of them had LBW, 9.2% had NICU, 3.7% had APGAR1
{"title":"Assessment of the prevalence of anemia and its complications among term pregnant women at Ain Shams University Maternity Hospital","authors":"M. Elmahallawi, M.R.C.O.G. Abdel-Hafeez, A. Hussein, Reham Mahmoud","doi":"10.21608/ebwhj.2019.17524.1030","DOIUrl":"https://doi.org/10.21608/ebwhj.2019.17524.1030","url":null,"abstract":"Background: Global prevalence of anemia in pregnant women is 41.8%, approximately 50% of cases of anemia are considered to be due to iron deficiency. Aim of the Work: to assess the prevalence of anemia and its complications among term pregnant women at Ain Shams University Maternity Hospital. Patients and Methods: This retrospective study was conducted on hospital records of 1552 pregnant women from January 2018 to July 2018 . Results: Hb was 11.3±1.4 gm/dL, 59.1% of patients were normal and 40.9% had anemia in form of Mild in 28.3%, Moderate in 11.3% and Severe in 1.3%.. As regard neonatal outcome mean gestational age was 38.8±0.9 weeks, birth weight 3.13±0.56 kg, Apgar 1st was 8.4±1.2, 5th was 8.5±1.1. As regard neonatal complications 9.35 of them had LBW, 9.2% had NICU, 3.7% had APGAR1","PeriodicalId":224226,"journal":{"name":"Evidence Based Womenʼs Health Journal","volume":"92 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2020-12-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"132454037","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-12-06DOI: 10.21608/ebwhj.2020.28158.1093
Mohammad Soroura, Maged El Shorbagy, M. Shawky, T. Borg, K. Wahba, A. Reyad
Background: Pre-eclampsia is a pregnancy-specific disorder that has a worldwide prevalence of 5–15%. It is one of the main causes of maternal and perinatal morbidity and mortality globally and accounts for 50 000–60 000 deaths annually, with a predominance in the low- and middle-income countriesThere is a great need to have a test for predicition of women at high risk of developing preeclampsia. Aim of the Work: to assess the accuracy of maternal serum Cff-DNA concentration levels in primigravidas 10-20 weeks gestation as a predictive test for the development of preeclampsia. Patients and Methods: A nested case-control study was conducted on 26 patients with PE and 26 matched controls rimigravidas in 10-20 weeks gestation recruited from Ain-Shams University Maternity Hospital. Laboratory work was done in Ali Khalifa laboratory of the biochemistry department, Faculty of Medicine, Ain-Shams University. Results: The study showed a statistically significant increase median of severe preeclampsia compared to non severepreeclampsia and control group according to cff-DNA (GE/ml). Also the study results revealed a statistically significant increase median of preeclampsia group compared to control group according to BMI, GA (wks), SBP and DBP. Conclusion: Cff-DNA quantification can be considered as a promising marker for preeclampsia prediction, especially for the development of early-onset or severe preeclampsia.
{"title":"Circulating Maternal Serum Cell Free Fetal DNA Levels for prediction of Preeclampsia","authors":"Mohammad Soroura, Maged El Shorbagy, M. Shawky, T. Borg, K. Wahba, A. Reyad","doi":"10.21608/ebwhj.2020.28158.1093","DOIUrl":"https://doi.org/10.21608/ebwhj.2020.28158.1093","url":null,"abstract":"Background: Pre-eclampsia is a pregnancy-specific disorder that has a worldwide prevalence of 5–15%. It is one of the main causes of maternal and perinatal morbidity and mortality globally and accounts for 50 000–60 000 deaths annually, with a predominance in the low- and middle-income countriesThere is a great need to have a test for predicition of women at high risk of developing preeclampsia. Aim of the Work: to assess the accuracy of maternal serum Cff-DNA concentration levels in primigravidas 10-20 weeks gestation as a predictive test for the development of preeclampsia. Patients and Methods: A nested case-control study was conducted on 26 patients with PE and 26 matched controls rimigravidas in 10-20 weeks gestation recruited from Ain-Shams University Maternity Hospital. Laboratory work was done in Ali Khalifa laboratory of the biochemistry department, Faculty of Medicine, Ain-Shams University. Results: The study showed a statistically significant increase median of severe preeclampsia compared to non severepreeclampsia and control group according to cff-DNA (GE/ml). Also the study results revealed a statistically significant increase median of preeclampsia group compared to control group according to BMI, GA (wks), SBP and DBP. Conclusion: Cff-DNA quantification can be considered as a promising marker for preeclampsia prediction, especially for the development of early-onset or severe preeclampsia.","PeriodicalId":224226,"journal":{"name":"Evidence Based Womenʼs Health Journal","volume":"19 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2020-12-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"123853834","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-12-06DOI: 10.21608/ebwhj.2020.19975.1057
Raghda Ayman Abouelela, A. Hussien, Abdel M. Mageed, Manal Fawzy Gabr
Background: Recurrent pregnancy loss is considered as a major devastating obstetric and gynecological health problem. Many clinicians define RPL as three or more consecutive pregnancies ending spontaneously before the 20th week of gestation. Aim of the Work: to investigate prevalence of FVL mutation in women with RPL using, a less time and money consuming test, APCR test. Patients and Methods: We compared the prevalence of FVL among 83 patients with history of 3 or more first tri-mesteric pregnancy losses (the case group) with an equal number of women with no history of RPL (the control group), recruited from the RPL outpatient clinic at the Obstetrics and Gynecology Department of Ain Shams University Maternity Hospital, during the period between April 2018 till June 2019. Results: Abnormal APCR test values were found in a total of 22 women in our study, 7 women in the control group (8.4%) and 15 in the case group (18.07%) with no statistically significant differences. However, in further assessment of case group, two patients in the case group with abnormal APC value, suffered from DVT episodes, representing 13.3% of 15 patient with abnormal APCR. The P value was statistically significant, which mean that the present of APCR might increase the risk for DVT Conclusion: Isolated FVL is unlikely to be an important cause for RPL as no statistically significant difference is found between the case and control groups.
{"title":"The Association of Factor V Leiden Mutation With Recurrent Pregnancy Loss Using Activated Protein C Resistance Test (Case-Control Study)","authors":"Raghda Ayman Abouelela, A. Hussien, Abdel M. Mageed, Manal Fawzy Gabr","doi":"10.21608/ebwhj.2020.19975.1057","DOIUrl":"https://doi.org/10.21608/ebwhj.2020.19975.1057","url":null,"abstract":"Background: Recurrent pregnancy loss is considered as a major devastating obstetric and gynecological health problem. Many clinicians define RPL as three or more consecutive pregnancies ending spontaneously before the 20th week of gestation. Aim of the Work: to investigate prevalence of FVL mutation in women with RPL using, a less time and money consuming test, APCR test. Patients and Methods: We compared the prevalence of FVL among 83 patients with history of 3 or more first tri-mesteric pregnancy losses (the case group) with an equal number of women with no history of RPL (the control group), recruited from the RPL outpatient clinic at the Obstetrics and Gynecology Department of Ain Shams University Maternity Hospital, during the period between April 2018 till June 2019. Results: Abnormal APCR test values were found in a total of 22 women in our study, 7 women in the control group (8.4%) and 15 in the case group (18.07%) with no statistically significant differences. However, in further assessment of case group, two patients in the case group with abnormal APC value, suffered from DVT episodes, representing 13.3% of 15 patient with abnormal APCR. The P value was statistically significant, which mean that the present of APCR might increase the risk for DVT Conclusion: Isolated FVL is unlikely to be an important cause for RPL as no statistically significant difference is found between the case and control groups.","PeriodicalId":224226,"journal":{"name":"Evidence Based Womenʼs Health Journal","volume":"21 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2020-12-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"133714735","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-12-06DOI: 10.21608/ebwhj.2019.17263.1022
A. Elgendy, Ahmed Ahmed, A. S. El-Houssieny, H. Gad
Abdominal myomectomy is a major operation. Massive blood loss is the most serious complication which should be taken in consideration to decrease morbidity and mortality. There are several modalities to decrease blood loss approached in different studies as preoperative GnRh, uterine artery tourniquet, tranexamic acid, vasopressin …etc.The aim of the study was to assess the role of vasopressin injection intramyometrial in decreasing blood loss during abdominal myomectomy.This study is an RCT which was conducted at Ain Shams University Maternity Hospital on 60 women with uterine fibroid admitted for abdominal myomectomy to detect if vasopressin injection intramyometrial had a role in decreasing blood loss versus placebo or not.The end results showed that that the mean of blood loss was 826.67cc with standard deviation 185.94 and 115.53cc with standard deviation 23.17 at control and vasopressin group respectively with p- value
{"title":"Role of Vasopressin Injection Intramyometrial in Decreasing Blood Loss During Abdominal Myomectomy (A Randomized Controlled Trial)","authors":"A. Elgendy, Ahmed Ahmed, A. S. El-Houssieny, H. Gad","doi":"10.21608/ebwhj.2019.17263.1022","DOIUrl":"https://doi.org/10.21608/ebwhj.2019.17263.1022","url":null,"abstract":"Abdominal myomectomy is a major operation. Massive blood loss is the most serious complication which should be taken in consideration to decrease morbidity and mortality. There are several modalities to decrease blood loss approached in different studies as preoperative GnRh, uterine artery tourniquet, tranexamic acid, vasopressin …etc.The aim of the study was to assess the role of vasopressin injection intramyometrial in decreasing blood loss during abdominal myomectomy.This study is an RCT which was conducted at Ain Shams University Maternity Hospital on 60 women with uterine fibroid admitted for abdominal myomectomy to detect if vasopressin injection intramyometrial had a role in decreasing blood loss versus placebo or not.The end results showed that that the mean of blood loss was 826.67cc with standard deviation 185.94 and 115.53cc with standard deviation 23.17 at control and vasopressin group respectively with p- value","PeriodicalId":224226,"journal":{"name":"Evidence Based Womenʼs Health Journal","volume":"1 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2020-12-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"130830761","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-11-01DOI: 10.21608/ebwhj.2020.42330.1105
H. Nabil, H. Youssef, S. Tawfeek, W. Elrefaie
Background: Spasmodic dysmenorrhea is one of the commonest painful attacks that affects young ladies. Non steroidalanti-inflammatory (NSAID) drugs are considered as one of the main treatment options. Different pain management modalities concern with pretreatment with analgesia before the painful stimuli that defined as preemptive analgesia.Aim: This study aimed to evaluate the possible effect of administration of NSAIDs before the onset of pain in the anticipating menstrual cycle. Materials and Methods: One hundered young ladies ranged from 15-25 years old were randomly divided into two groups. Group 1 received mefinamic acid 2 days before the anticipating date of menstruation and continued throughout the first 2 days of menstruation and group 2 received the same medication however started with the onset of symptoms only. Results: Both groups were comparable regarding age, education and menstrual characters. The average pain score was nearly the same in both groups (8.78 ± 1.07 and 8.66 ± 1.04) and it was significantly decrease after intervention in both groups. The decrease in pain score was more in the girls treated before menstruation (4.24 ± 1.57) compared to (7.20 ± 1.77) in the girls treated after onset of menstruation and the difference was statistically significant. The percentage decrease in pain score among the girls of premenstrual treatment ranged from 14.28% to 80.0% with median decrease 55.56%, compared to 0.0% to 62.5% with median decrease 10.56% in the group treated at onset of menstruation. The difference was also statistically significant (P <0.001). Conclusion: NSAIDS can be used effectively to prevent and control primary dysmenorrhea associated symtoms if used before the appearance of symptoms, and targeted groups are in great chance to practice an easier life throughout the entiremenstrual cycle.
{"title":"Preemptive analgesia for primary dysmenorrhea : A randomized controlled clinical trial","authors":"H. Nabil, H. Youssef, S. Tawfeek, W. Elrefaie","doi":"10.21608/ebwhj.2020.42330.1105","DOIUrl":"https://doi.org/10.21608/ebwhj.2020.42330.1105","url":null,"abstract":"Background: Spasmodic dysmenorrhea is one of the commonest painful attacks that affects young ladies. Non steroidalanti-inflammatory (NSAID) drugs are considered as one of the main treatment options. Different pain management modalities concern with pretreatment with analgesia before the painful stimuli that defined as preemptive analgesia.Aim: This study aimed to evaluate the possible effect of administration of NSAIDs before the onset of pain in the anticipating menstrual cycle. Materials and Methods: One hundered young ladies ranged from 15-25 years old were randomly divided into two groups. Group 1 received mefinamic acid 2 days before the anticipating date of menstruation and continued throughout the first 2 days of menstruation and group 2 received the same medication however started with the onset of symptoms only. Results: Both groups were comparable regarding age, education and menstrual characters. The average pain score was nearly the same in both groups (8.78 ± 1.07 and 8.66 ± 1.04) and it was significantly decrease after intervention in both groups. The decrease in pain score was more in the girls treated before menstruation (4.24 ± 1.57) compared to (7.20 ± 1.77) in the girls treated after onset of menstruation and the difference was statistically significant. The percentage decrease in pain score among the girls of premenstrual treatment ranged from 14.28% to 80.0% with median decrease 55.56%, compared to 0.0% to 62.5% with median decrease 10.56% in the group treated at onset of menstruation. The difference was also statistically significant (P <0.001). Conclusion: NSAIDS can be used effectively to prevent and control primary dysmenorrhea associated symtoms if used before the appearance of symptoms, and targeted groups are in great chance to practice an easier life throughout the entiremenstrual cycle.","PeriodicalId":224226,"journal":{"name":"Evidence Based Womenʼs Health Journal","volume":"297 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2020-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"115862376","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：